Adv. Shahaf was appointed to the position of Managing Director of Hadasit Bio-Holdings Ltd. - the publicly traded subsidiary of Hadasit, upon its IPO – in January 2006. He was promoted to the position of CEO in March, 2007. Mr. Shahaf is responsible for all of the ongoing activities of the public entity, including financial, legal, IR/PR, investment and fundraising issues.
Prior to this position, he served as VP business development at Protalix Biotherapeutics Ltd., a biopharmaceutical company focusing on the expression of human recombinant proteins in plant cell cultures. Adv. Shahaf was a part of the founding and management team of Clal Biotechnology Industries Ltd. – Israel's largest corporate investor in the life sciences, where he served as VP and general counsel, and participated in the management and investment of over $ 100 M.
Adv. Shahaf received his law degree from Tel Aviv University, and his MBA from the Stern School of Business at New York University, with a major in finance and international business. He teaches several courses in biotechnology entrepreneurship and management and is a fellow of the Merage Foundation at Irvine, CA. Mr. Shahaf is a father of 3 and resides in Tel-Aviv.
